Search Results - "Goulden, Nicholas John"

Predictors of Relapse Risk Do Not Influence Time to “Cure” in Children and Young Adults with Acute Lymphoblastic Leukaemia by Samarasinghe, Sujith, Vora, Ajay, Goulden, Nicholas John, Antony, Grace, Moorman, Anthony V.

“…After how many years from diagnosis/completing treatment should children and young adults with acute lymphoblastic leukaemia be considered “cured”? Clinical…”
Get full text

Ten Year Outcomes of UKALL 2003: A Randomised Clinical Trial of Adjusting Treatment Intensity Based on Minimal Residual Disease by Samarasinghe, Sujith, Vora, Ajay, Goulden, Nicholas John, Antony, Grace, Moorman, Anthony V.

“…▪ The UKALL 2003 trial aimed to safely reduce treatment intensity in low-risk patients and intensify therapy in high-risk patients based on minimal residual…”
Get full text

Major Deviations in the Delivery of Induction Chemotherapy Are Associated with an Increased Risk of Relapse in Acute Lymphoblastic Leukaemia: Results from UKALL2003 by Hough, Rachael E, Kirkwood, Amy A, Samarasinghe, Sujith, Rowntree, Clare J, Goulden, Nicholas John, Vora, Ajay

“…Introduction As survival rates for acute lymphoblastic leukaemia (ALL) in children and young people improve, the need to understand and mitigate toxicity…”
Get full text

Preliminary Outcomes of Children and Young Adults with Acute Lymphoblastic Leukaemia and Down Syndrome (DS-ALL) on UKALL 2011. Reduction in Treatment-Related Mortality with De-Escalated Therapy by Ghorashian, Sara, Samarasinghe, Sujith, Kirkwood, Amy A, Hough, Rachael, Rowntree, Clare, Lawson, Sarah, Goulden, Nicholas John, Pond, Emma, Kearns, Pamela R., Moorman, Anthony V., Moppett, John, Vora, Ajay

“…Introduction Reported outcomes for children with Downs syndrome (DS) and acute lymphoblastic leukaemia (ALL) treated on our previous national study, UKALL…”
Get full text

Dexamethasone Pharmacokinetics Following Standard and Short Dosing Schedules in Patients on the UKALL2011 Trial by Jackson, Rosanna, Berry, Philip, Errington, Julie, Moppett, John, Samarasinghe, Sujith, Hough, Rachael, Rowntree, Clare, Goulden, Nicholas John, Vora, Ajay, Kearns, Pamela R., Irving, Julie, Veal, Gareth J

“…Dexamethasone (Dex) is a key component of ALL therapy, with glucocorticoid sensitivity strongly linked to prognosis. However, it also contributes to both short…”
Get full text

UKALL 2011: Randomised Trial Investigating a Short Induction Dexamethasone Schedule for Children and Young Adults with Acute Lymphoblastic Leukaemia by Goulden, Nicholas John, Kirkwood, Amy A, Moppett, John, Samarasinghe, Sujith, Lawson, Sarah, Rowntree, Clare, Hough, Rachael, Athwal, Rajbir, Kearns, Pamela R., Vora, Ajay

“…▪ Dexamethasone is associated with a higher risk of infectious and non-infectious morbidity and mortality than prednisolone in induction therapy of children…”
Get full text

Therapy of Paediatric B-ALL with a Fast Off Rate CD19 CAR Leads to Enhanced Expansion and Prolonged CAR T Cell Persistence in Patients with Low Bone Marrow Tumour Burden, and Is Associated with a Favourable Toxicity Profile by Ghorashian, Sara, Kramer, Anne Marijn, Onuoha, Shimobi, Wright, Gary, Bartram, Jack Luke, Richardson, Rachel, Albon, Sarah J, Casanovas Company, Joan, Castro, Fernanda, Popova, Bilyana, Villanueva, Krystal, Yeung, Jenny, Guvenel, Aleks, Wawrzyniecka, Patrycja, Pinner, Danielle, Chu, Jan, Lucchini, Giovanna, Silva, Juliana, Ciocarlie, Oana, Lazareva, Arina, Inglott, Sarah, Gilmour, Kimberly, Ahsan, Gulrukh, Champion, Kim, Lopes, Andre, Hackshaw, Allan, Farzaneh, Farzin, Chiesa, Robert, Rao, Kanchan, Bonney, Denise, Samarasinghe, Sujith, Goulden, Nicholas John, Vora, Ajay, Veys, Paul, Hough, Rachael E, Wynn, Robert, Pule, Martin, Amrolia, Persis J

“…Introduction: The CARPALL study (NCT02443831) employed a novel CD19CAR (CAT-41BBz CAR) with a faster off rate than the Kymriah FMC63-41BBz CAR (CAT…”
Get full text